-+ 0.00%
-+ 0.00%
-+ 0.00%

KARYOPHARM'S PHASE 3 SENTRY TRIAL OF SELINEXOR PLUS RUXOLITINIB IN MYELOFIBROSIS SELECTED FOR LATE-BREAKING ORAL PRESENTATION AT EHA 2026

Reuters·06/02/2026 14:03:09

Please log in to view news